BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Jun 28, 2004
 |  BioCentury  |  Strategy

Schering's core pipeline

Schering's core pipeline

Product Indication Status Partner
Women's healthcare
Yasmin drospirenone low dose Oral contraceptive Registration
Acne Ph III (registration 2005)
Premenstrual dysphoric disorder (PMDD) Ph III (data 4Q04; registration 2005)
Menostar transdermal ultra-low dose estradiol Osteoporosis Approved in U.S.; registration in EU (U.S. launch 2004; EU launch 2005)
Angeliq (U.S.)...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >